China Galaxy released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a recommended rating. The main reasons for the rating include: 1) the main business segments are growing steadily, and the pharmaceutical business and overseas medicine and aesthetics are under pressure in the short term; 2) R&D in the pharmaceutical industry is progressing smoothly, and several products have reached important points; 3) registration of key medical and aesthetic products has been accepted, and the product matrix is getting richer. (Mainichi Keizai Shimbun)
中国银河4月28日发布研报称，给予华东医药（000963.SZ）推荐评级。评级理由主要包括：1）主要业务板块增长稳健，医药商业和海外医美短期承压；2）医药工业研发进展顺利，多个产品达到重要节点；3）重点医美产品注册受理，产品矩阵日渐丰富。（每日经济新闻）
China Galaxy released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a recommended rating. The main reasons for the rating include: 1) the main business segments are growing steadily, and the pharmaceutical busines
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.